DENINE BALDOR: Open Payments
NPI 1982910485 · OAKLAND, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$929 in 38 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $64 · 2025 $929
Food & beverage: $902Education: $27
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 8 | $190 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $157 |
| Alkermes, Inc. | 6 | $142 |
| Teva Pharmaceuticals USA, Inc. | 3 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $93 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| Janssen Pharmaceuticals, Inc | 2 | $52 |
| Tris Pharma Inc | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Lundbeck LLC | 1 | $27 |
Products named: COBENFY, CAPLYTA, ARISTADA, TRINTELLIX, REXULTI, FANAPT, INVEGA SUSTENNA, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
